<DOC>
	<DOCNO>NCT01731561</DOCNO>
	<brief_summary>The aim study assess efficacy rituximab regimen base rate ANCA CD19 lymphocytes maintenance treatment systemic ANCA-associated vasculitis : prospective , multicenter , control , randomize comparative study two rituximab regimen : one base ANCA CD19 lymphocytes versus systematic infusion .</brief_summary>
	<brief_title>Comparison Study Two Rituximab Regimens Remission ANCA Associated Vasculitis</brief_title>
	<detailed_description>Randomized , control , national , multicenter , prospective study compare systematic rituximab infusion ( conventional therapy ) rituximab infusion base rate ANCA CD19 lymphocytes patient systemic ANCA-associated vasculitis , remission ( achieve induction treatment combine corticosteroid immunosuppressant first flare disease ( new diagnosis ) relapse . Patients stratify first flare ( 66 % patient ) relapse ( 33 % patient ) . Patients comply inclusion criterion may include remission vasculitis . Patients include time remission randomize . They receive maintenance treatment 1 ) 2 rituximab infusion mg D1 , D15 every 6 month month 18 ( i.e . total 5 infusion ) , dose 500 mg. 2 ) 1 rituximab infusion dose 500 mg D0 ANCA status CD19+ lymphocyte count monitor every 3 month , patient receive new 500 mg rituximab infusion either CD19 &gt; 0/mm3 , ANCA positive ANCA titer significantly raise . After 18 month length maintenance phase , i.e . stop immunosuppressive maintenance therapy , patient follow additional 10 month period . Patients granulomatosis polyangiitis prescribe cotrimoxazole 160/800 tid ( 2 additional year ) .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Granulomatosis Polyangiitis Or microscopic polyangiitis comply Or kidneylimited disease With without detectable ANCA ( antineutrophil cytoplasmic antibody ) time diagnosis relapse , remission . Who achieve remission use treatment combine corticosteroid immunosuppressive agent , include corticosteroid , cyclophosphamide IV oral ( use another immunosuppressant allow , accord current French guideline , well plasma exchange and/or IV immunoglobulin , rituximab ) . Interval 1 month end immunosuppressant treatment randomization time cyclophosphamide methotrexate use , interval 4 6 month rituximab use Age &gt; 18 year without age limit high diagnosis confirm . Informed signed consent form take part study . Other systemic vasculitis Secondary vasculitis ( follow neoplastic disease infection particular ) Induction treatment regimen correspond recommend France . Patient achieve remission . Incapacity refusal understand sign inform consent form . Incapacity refusal adhere treatment perform followup examination require study . Noncompliance Allergy , document hypersensitivity contraindication study medication ( cyclophosphamide , corticosteroid , azathioprine , rituximab ) History severe allergic anaphylactic reaction humanize murine monoclonal antibody . Pregnancy , breastfeed . Women childbearing age must use reliable method contraception throughout duration immunosuppressive treatment 1 year last infusion rituximab Infection HIV , HCV HBV Progressive , uncontrolled infection require prolong treatment ( tuberculosis , HIV infection , etc. ) . Severe infection declare 3 month randomization ( CMV , HBV , HHV8 , HCV , HIV , tuberculosis ) . Progressive cancer malignant blood disease diagnose 5 year diagnosis vasculitis . Patients suffer nonmetastatic prostate cancer cure cancer malignant blood disorder 5 year take antineoplastic agent 5 year may include . Participation another clinical research protocol 4 week inclusion . Any medical psychiatric disorder , investigator 's opinion , may prevent administration treatment patient followup accord protocol , and/or may expose patient great risk adverse effect . No social security Churg Strauss syndrome Viral , bacterial fungic mycobacterial infection uncontrolled 4 week inclusion History deep tissue infection ( fasciitis , osteomyelitis , septic arthritis ) first year inclusion History chronic severe recurrent infection history preexist disease predispose severe infection Severe immunodepression Administration live vaccine four week inclusion Severe chronic obstructive pulmonary disease ( VEMS &lt; 50 % dyspnea grade III ) Chronic heart failure stade III IV ( NYHA ) History recent acute coronary syndrome , unrelated vasculitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Granulomatosis Polyangiitis</keyword>
	<keyword>Microscopic polyangiitis</keyword>
	<keyword>Renal limit form</keyword>
	<keyword>ANCA-associated vasculitis</keyword>
	<keyword>Rituximab</keyword>
</DOC>